Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/insertable-cardiac-monitors-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Insertable Cardiac MonitorsInsertable Cardiac Monitor Patents: Ownership, Filing Trends and Open Claim Space
- 90.0% concentration. The top 5 of 26 ranked assignees hold 911 of 1,012 records in scope — a field with almost no room left at the centre of the claim map.
- Filings down 53% since the 2021 peak-adjacent year. 2021 filings of 120 fell to 56 by 2024, the last year the trend can be read as complete; 2025-2026 figures are still filling in under normal publication lag.
- Sensing and power electronics are thin. H04B transmission, H02J power supply and G06N AI-based analysis each sit under 2% of the 1,012 records, well behind the A61B and A61N core.
1,012
Published Records
90%
Top-5 Share of All Records
-53%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (120 records) with 2024 (56) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,012 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview
What the insertable cardiac monitor patent record shows
Insertable cardiac monitors — leadless, subcutaneously implanted devices that continuously record cardiac electrical activity — sit at the intersection of implant hardware, sensing algorithms and remote data transmission. The 1,012 records in this scope span 2015 through mid-2026 and cluster heavily around diagnosis-and-surgery (A61B) and electrotherapy (A61N) classifications, the two classes that between them cover the device housing, electrode placement and signal-detection claims that define the category. Sensing vector selection, false-episode discrimination and device longevity are the recurring technical hooks across the search terms, reflecting where competitive claims have actually been drafted rather than where the science is theoretically richest.
Ownership is heavily concentrated: five companies hold ninety percent of all records, and ten hold essentially all of them. That leaves a long tail of single- or few-filing entrants competing for whatever claim space the leaders have not already occupied — mostly in transmission protocols, power management and AI-based signal analysis, where filing counts are still in the low tens.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Data
Filing trend and technology composition
Two views of the same 1,012 records: how filing activity has moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017-2026
Filings peaked at 131 in 2017. The last year that can be read as a complete data point is 2024, at 56 — down from 120 in 2021, a 53% drop across that three-year span. 2025 and 2026 figures will continue to rise as publications catch up with roughly an 18-month filing-to-publication lag; they should not yet be read as a further decline.
Technology composition by IPC subclass
A61B (diagnosis and surgery) and A61N (electrotherapy) dominate, covering 68.2% and 60.8% of the 1,012 records respectively — many records carry both. G16H healthcare informatics trails at 13.8%, and transmission (H04B), power supply (H02J) and AI-based computing (G06N) each sit at or below 1.9%, marking the thinnest-claimed branches of the field.
Shares are the percentage of the 1,012 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Insertable Cardiac Monitors with Eureka
This page is one run against one query. Ask Eureka your own question about insertable cardiac monitors and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records anchoring this field
Representative Filing
US20180078771A1 — Implantable cardiac monitor
CARDIAC PACEMAKERS, INC.
The filing describes a subcutaneous, submuscular or substernal implantable cardiac monitor with a body-and-tail housing carrying three electrodes, and a controller that selects among electrode pairs to sense cardiac activity. The tail-mounted third electrode and pair-selection logic are the structural features most likely to be asserted against competing form factors.Assignee and filing date are shown in the table above.
Highest-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6230059B1 | Implantable monitor | 741 |
| 2 | US6067473A | Implantable medical device using audible sound communication to provide warnings | 455 |
| 3 | US5891180A | Interrogation of an implantable medical device using audible sound communication | 329 |
| 4 | US20040049120A1 | Methods and apparatus for cardiac R-wave sensing in a subcutaneous ECG waveform | 312 |
| 5 | US7027858B2 | Methods and apparatus for cardiac R-wave sensing in a subcutaneous ECG waveform | 235 |
| 6 | US20160144192A1 | Cardiac pacing sensing and control | 175 |
| 7 | US20140088442A1 | Method and device to monitor patients with kidney disease | 145 |
| 8 | US20120277546A1 | Method and device to monitor patients with kidney disease | 140 |
| 9 | US8626280B2 | Methods and devices for accurately classifying cardiac activity | 139 |
| 10 | US9289612B1 | Coordination of ventricular pacing in a leadless pacing system | 138 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing or freedom-to-operate decision
Three patterns stand out once the record set is broken down by ownership, technology class and time.
Concentration
90.0% of 1,012
held by top 5 assignees
The core claim space is not open
Five assignees hold 911 of the 1,012 records in scope. Anyone entering the housing, electrode-placement or core sensing space is filing directly against incumbents who have already built dense, overlapping claim positions there.
Top 5 of 26 ranked assignees
Momentum
120 → 56
annual filings, 2021-2024
Filing pace has cooled from its recent high
The -53% move from 2021 to 2024 is the last complete comparison the data supports. It reads as a mature, heavily-claimed core rather than an abandoned one — incumbents defending existing positions typically file less once the housing and sensing claims are settled.
2024 is the last complete year; 2025-2026 will still rise
Technology mix
1.9% or less
share of records in H04B, H02J, G06N
Transmission, power and AI analytics are thinly claimed
Remote transmission (H04B), power supply management (H02J) and AI-based signal processing (G06N) each sit under 2% of the 1,012 records, versus 68.2% for A61B alone. That gap is where new claim scope is most available relative to the crowded implant-hardware core.
Compare to A61B at 68.2% and A61N at 60.8%
Collaboration
8 co-filings
strongest inventor pairing
Inventor teams recur across related filings
The strongest co-assignee pairings in the data appear at 8 shared filings among the same small group of named inventors, suggesting a compact internal team authored a meaningful share of one leader's sensing-related claims.
10 co-assignee pairs identified in scope
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insertable cardiac monitors, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing
Ownership is concentrated at the top, with a long tail below
Twenty-six assignees make up the entire ranked list the data endpoint returns for this scope — not a top-50 or top-100 cut, the full set. The distribution is steep: fifth place already sits at 58 records, tenth place at just 8.
Leader position
515 records
leading assignee
One filer dominates the leaderboard
The top-ranked assignee alone accounts for roughly half of all 1,012 records in scope, a scale gap that separates it from every other name on the list.
Fifth place: 58 records
Mid-tier drop-off
58 → 8
records, 5th to 10th place
The mid-tier thins out fast
Filing counts fall sharply between fifth and tenth place, meaning the meaningful competitive set for freedom-to-operate purposes is smaller than the full 26-company ranking suggests.
Top 10 combined: 99.3% of all records
Recent momentum
-77% to -100%
YoY change, latest year
Momentum is down across nearly every ranked filer
Every assignee with visible recent-year activity in the data shows a year-over-year decline, several to zero filings, though the most recent year is still incomplete under normal publication lag and should not be read as a hard stop.
Latest-year filings still filling in for 2025-2026
Filing momentum by assignee, latest complete years
| Assignee | Recent year | YoY |
|---|---|---|
| Medtronic, Inc. | 3 | -90% |
| PACESETTER INC | 3 | -77% |
| ATACOR MEDICAL INC | 0 | -100% |
| Cardiac Pacemakers, Inc. | 0 | -100% |
| Cameron Health, Inc. | 0 | — |
| Biotronik SE & Co. KG | 0 | -100% |
| Bardy Diagnostics, Inc. | 0 | — |
| Covidien LP | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to a handful of concrete next steps depending on whether the goal is filing strategy, freedom-to-operate or competitive tracking.
Map claims against the thin branches
Run a claim-level search inside H04B, H02J and G06N to see exactly what the small number of existing filings there actually cover before drafting into that space.
Explore technology white space in EurekaTrack the leading assignee's recent activity
With one filer holding roughly half of all records, monitoring its newest publications is the fastest way to see where the core claim boundary is moving next.
Set up assignee monitoring in EurekaWatch the 2025-2026 publication catch-up
Because publication lags filing by about 18 months, re-check the 2024-2026 trend again once later-year records finish publishing, rather than treating the current dip as final.
Revisit filing trends in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on insertable cardiac monitor patents
Ownership in this field is highly concentrated: the leading assignee alone accounts for 515 of the 1,012 records in scope, and the top five assignees together hold 90.0% of all records. The remaining filers form a long tail, with counts dropping to single digits by tenth place. This means freedom-to-operate analysis in the implant-hardware core realistically only needs to focus on a handful of companies, not the full 26-name ranking.
Filing activity peaked in 2017 at 131 records and has since declined, falling from 120 in 2021 to 56 in 2024, a 53% drop across that span. 2024 is the last year that can be treated as a complete data point; 2025 and 2026 figures will keep rising as publications catch up, since publication typically lags filing by about 18 months. The honest read is a maturing, heavily-claimed core rather than a shrinking field.
The core diagnosis-and-surgery (A61B) and electrotherapy (A61N) classes are saturated, covering 68.2% and 60.8% of all 1,012 records respectively. Transmission (H04B), power supply management (H02J) and AI-based signal computing (G06N) each sit at or below 1.9% of records, marking them as comparatively thin. Anyone targeting remote data transmission, battery longevity management or AI-based false-episode discrimination is filing into much lower-density claim territory than the implant-housing core.
This filing, assigned to Cardiac Pacemakers, Inc., describes an implantable cardiac monitor with a body-and-tail housing carrying three electrodes and a controller that selects among electrode pairs to sense cardiac activity. Its most defensible features are the tail-mounted third electrode geometry and the electrode-pair selection logic, which together shape how competing form factors position their own sensing electrodes. Designing around it typically means avoiding both the specific tail-electrode placement and the described pair-selection method, or licensing around it.
The most-cited records in this dataset date back to the late 1990s and early 2000s, reflecting the fact that citation counts accumulate over time within a searched corpus. A patent filed in 2023 has not had the years needed to accrue equivalent citations even if its technical content is more directly relevant to current products. Citation count should be read as a signal of historical influence on the field's foundational claims, not as a measure of which patents matter most today.
Answers are grounded in the same dataset. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Insertable Cardiac Monitors in depth with Eureka
Go past this page: query the whole insertable cardiac monitors corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.